Next, we assessed whether in vivo PD-L1 blockade could potentiate the therapeutic efficacy of PLK1122DC_TriVax vaccination in a more clinically relevant myeloid leukaemia setting. This evidence concerns the gene CD274 and myeloid leukemia.